PE-22-28 is a research-only peptide with no approved human dose. There is no medically established schedule; any amounts seen online are anecdotal and not standardized. This is education, not a personal protocol.
Overview
PE-22-28 is a synthetic analog of spadin, engineered in laboratory work with the aim of improving properties such as stability. It is an investigational, animal-stage compound — not an approved medicine — and it has not gone through the clinical dose-finding process that would define a human dose.
Is there a common dose?
Honestly, no standardized common dose exists:
- No established dose — PE-22-28 has no approved or clinically validated amount, and figures shared online vary widely and are not standardized.
- Preclinical evidence — its pharmacology is drawn from animal work, so any human amount would be speculative.
- Start low, with supervision — if handled at all, it belongs in controlled research under expert oversight, not self-experimentation.
We deliberately do not cite a number here, because a specific figure would imply a human standard that does not exist.
How it is discussed
A recurring theme with PE-22-28 is analog design: small structural changes to a peptide can alter how it behaves in solution and how long it persists. That is a conceptual point about why the molecule was engineered, not a settled route or administration standard — those remain undefined.
Why supervision matters
As an animal-stage compound, PE-22-28's safety profile, interactions, and appropriate candidates are not characterized in humans. There is no approved indication or monitoring standard. Any real-world handling belongs within controlled research under expert supervision — not a self-directed protocol.